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A B S T R A C T   
Background: Lewy Body dementia (LBD) is the second most prevalent neurodegenerative dementia. This form of 
dementia is notable for an aggressive disease course consisting of a combination of cognitive, Parkinsonian, 
affective, and physiological symptoms that significantly increase morbidity and mortality, and decrease life 
expectancy in this population compared to more common dementias. Additionally, those diagnosed with LBD are 
often excluded from trials evaluating exercise in similar diseases such as Alzheimer’s disease or Parkinson’s 
disease due to the complexity and concurrency of motor and cognitive symptoms. Consequently, there is scarce 
research evaluating the effect of exercise on individuals with LBD. 
Methods: The PRomoting Independence in Lewy Body Dementia through Exercise (PRIDE) trial is a novel non- 
randomised, crossover pilot study consisting of an 8-week wait-list usual care period, followed by an 8-week 
exercise intervention targeting progressive resistance and balance training. The trial aim is to evaluate the ef-
fect of exercise on the primary outcome of functional independence and secondary outcomes including cognitive, 
physical, psychosocial and quality of life measures in people living with LBD and their caregivers. The inter-
vention involves 3 supervised 1-h sessions per week (24 sessions in total) administered by an Accredited Exercise 
Physiologist in a clinical facility at the University of Sydney in Lidcombe, Australia. 
Discussion: The PRIDE study is the first controlled trial to evaluate a robust exercise intervention within a LBD 
cohort and will provide crucial information required to inform robust future clinical trials. 
Trial registration: Australia and New Zealand Trial Register (ANZCTR): ACTRN12616000466448; Key words: 
Lewy body; dementia; exercise; anabolic; functional independence.   
1. Introduction 
Lewy body dementia (LBD) is an umbrella term for the diseases of 
dementia with Lewy bodies (DLB), and Parkinson’s disease dementia 
(PDD) which share common pathology, and have a variable estimated 
prevalence of up to 24% of all dementia diagnosis [1]. LBD has complex, 
fluctuating symptomatology, including parkinsonism, psychosis, auto-
nomic and cognitive impairments; with afflicted individuals progressing 
more rapidly to residential care and death following diagnosis [2]. The 
prevalence of frailty in early LBD (37%) is double that of Alzheimer’s 
disease (AD) or Parkinson’s disease (PD) [3,4], and strongly associated 
with neuropsychiatric disturbances, poorer prognosis, lower quality of 
life and ultimately a reduction in functional independence [2]. Impor-
tantly, the rapid development of frailty in LBD is only minimally 
attributable to disease pathophysiology itself [5], with a greater 
involvement stemming from potentially treatable and highly prevalent 
risk factors in LBD including malnutrition, sarcopenia, delirium, infec-
tion, polypharmacy, injurious falls and behavioural disturbances 
[6–11]. However, current treatments for LBD are predominantly phar-
macological with significant risk of adverse outcomes, and do not 
effectively address the development of these risk factors or frailty in this 
cohort [12,13]. 
Conversely, non-pharmacological treatments such as exercise, which 
may offer a low-risk treatment option for improving frailty in LBD are 
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inadequately researched [14] and sub-optimally utilised. Guidelines for 
managing frailty in older adults recommend robust anabolic exercise 
such as progressive resistance training (PRT) to target the weakness, 
mobility impairment and sarcopenia at the core of the frailty phenotype 
[15]. However, the efficacy of any exercise, including PRT, is unknown 
in LBD, therefore can only be inferred from the substantial body of 
literature on exercise that exists in the two diseases sharing some fea-
tures of LBD: PD (for motor symptoms) and AD (for cognitive symp-
toms). Currently, anabolic exercise is increasingly recognised as an 
effective means to treat the cognitive and physical components of frailty 
in these two cohorts [16,17]. 
In PD for example, PRT significantly improves strength, physical 
function and balance, with higher training intensities and integration of 
challenging balance exercise further augmenting these improvements 
[18]. Cognition is also improved with resistance training over a two-year 
period [19], in contrast to the typical decline in cognition of 3.9% per 
year observed in this cohort [20]. Likewise, in frail dementia cohorts, 
PRT significantly improves cognition along with physical function, 
strength, and gait speed [21,22]. Furthermore, rapid improvement in 
muscle power (~30%), muscle volume (3–6%), and physical function 
(all of which contribute to frailty), are achievable in relatively short 
training programs of less than 3 months in both PD and dementia co-
horts [23,24]. Thus, there is a compelling rationale to suggest that an 
anabolic exercise intervention may be effective in the treatment of 
frailty in LBD, yet no published evidence of its utility or feasibility to our 
knowledge. Therefore, we designed the first trial evaluating robust ex-
ercise in this cohort; The PRomoting Independence in Lewy body Dementia 
through Exercise (PRIDE) Study. This trial will provide preliminary 
insight into the feasibility of anabolic exercise as a novel treatment for 
frailty and functional independence in LBD. 
1.1. Objectives and hypothesis 
The primary aims of the PRIDE study are to:  
1. Identify determinants of functional independence and quality of life 
(QoL) in individuals living with LBD that may be amenable to a 
targeted exercise intervention  
2. Assess the feasibility, including adoption and adherence, adverse 
events, and preliminary efficacy of this evidence-based exercise 
program on important clinical outcomes in individuals with LBD, as 
well as QoL and stress in their caregivers 
The primary hypotheses of the PRIDE study are:  
1. Low muscle strength and balance will be associated with impaired 
performance-based tests of function and functional dependency in 
LBD at baseline.  
2. A robust, progressive exercise intervention targeting strength and 
balance will improve functional independence in LBD, mediated in 
part by improvements in physiological capacity and performance- 
based tests of function. 
2. Materials and methods 
2.1. Study design 
The PRIDE study involves participants from both community and 
aged care residential settings, and is a non-randomised, unblinded, 
crossover trial. A crossover design was chosen due to the anticipated 
small number of patients with LBD in the local area available for 
recruitment. Randomisation to order of control vs. intervention period is 
not possible in this exercise intervention as it is anticipated to result in 
physiological adaptations with no predictable persistence of effect after 
exposure. Blinding of the interventionist and the participant is not 
possible due to the nature of the intervention compared to usual care. 
The assessor will not be blinded due to limited study resources. 
The study design consists of a baseline assessment, followed by an 8- 
week wait-list usual care period, then a crossover to an 8-week inter-
vention of anabolic exercise (Fig. 1). All assessment timepoints involve 
two separate assessment visits separated by one week and performed 
within the participant’s residence (baseline) or the clinical facility at 
Cumberland campus, University of Sydney in Lidcombe, Australia 
(Fig. 1). All outcomes are measured at baseline, before and after the 
intervention. Intervention length was chosen based on literature in PD 
and AD cohorts to be sufficient to demonstrate improvement in outcome 
measures [22,25]. The trial was prospectively registered prior to 
commencement of recruitment on 08/04/2016 (ANZCTR Reg. 
ACTRN12616000466448) [26]. 
2.2. Ethics 
Ethical approval was obtained from the University of Sydney Human 
Research Ethics (HREC 2: 2016/209). Consent is gained from caregivers 
for all participants, and written and/or verbal consent is gained from all 
participants where possible. The pride study adheres to the CONSORT 
guidelines for pilot trials [27] in the relevant sections. 
2.2.1. Participants recruitment 
Recruitment began in April 2016. Individuals with a diagnosis with 
LBD (either dementia with Lewy bodies or Parkinson’s disease demen-
tia) are recruited via geriatricians, neurologists, GPs, dementia and PD 
support groups and networks in the Sydney metropolitan area. Written 
informed consent of both the individual and caregiver is obtained. 
Inclusionary criteria include:  
 Diagnosis of LBD by a medical specialist which is confirmed by 
general practitioner  
 Age over 55  
 Ambulatory with/without assistance  
 Ability to follow rudimentary instructions  
 Ability to tolerate functional testing  
 Ability to travel to gym facility (with caregiver) and complete 3 
sessions/week for 8 weeks of exercise 
Exclusionary criteria include:  
 Inability to communicate in English 
 Major musculoskeletal, cardiovascular or other neurological condi-
tions precluding exercise as determined by study geriatrician  
 Inability to follow simple commands or mimic movements by the 
assessor/interventionist- 
2.2.2. Screening procedure 
Participants and/or their caregivers are screened over the telephone 
via a 1-h screening questionnaire to determine eligibility for the PRIDE 
trial and are read the participant information statement. Questions 
relating to demographics (inclusive of caregiver), study eligibility, 
physical activity, current health status, prior and current injury and 
illness, prescribed medications, and medical professionals associated 
with care of the participant are asked. Medical information is sought 
from participant’s GP or specialists after obtaining consent to further 
clarify eligibility as required. Additionally, comprehensive assessment 
of each participant is performed by the study geriatrician prior to 
commencing baseline one-repetition maximum (1RM) strength testing 
and exercise intervention. 
2.2.3. Estimated sample size 
Based upon similar cross-sectional studies in PD, to be able to show 
moderate correlations (r  0.5) with β  0.20 and α  0.05 for the 
baseline cross-sectional analysis, we calculate a minimum of 30 partic-
ipants would be needed, taking into consideration a 20% expected 
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attrition rate. The power calculation for the fixed period crossover trial 
requires a minimum of 24 participants to demonstrate significance for 
an effect size of 0.61 (with β  0.20 and α  0.05). These calculations are 
based upon results described in Rose and colleagues [25], who trained a 
cohort of individuals with moderate to severe PD for 8 weeks with the 
same primary functional independence outcome measure (MDS-UPDRS) 
we propose for PRIDE, but using an aerobic intervention. 
2.2.4. Assessment procedures 
The study coordinator, an accredited exercise physiologist (AEP), 
performs all assessment and intervention procedures with participants 
with the exception of the physician screen performed by the study 
geriatrician. The assessor is experienced in neuropsychiatric assessment, 
exercise training and assessment, and has completed required accredi-
tation for administration of the MDS-UPDRS and FIM measures. There 
are two 4-h assessment sessions at baseline, before intervention and 
after intervention (Fig. 1) with an additional 3-h assessment session at 
baseline at the clinic, which includes the physician screen prior to 6-min 
walk test, and 1RM strength testing. 
2.3. Intervention 
2.3.1. Wait-listed usual care period 
The wait-list usual care period involves the participant and caregiver 
continuing normal daily activities and routines. The study coordinator 
calls the caregiver weekly to monitor the status of the participant, and 
record any adverse events or changes in medications prescribed by the 
participant’s health care providers. 
2.3.2. Exercise intervention 
Exercise training is conducted in the medically supervised clinic at 
the University of Sydney Cumberland campus (Lidcombe, Australia). 
Training sessions are conducted 3 day/week and have a maximum 
duration of 60 min each session. An AEP supervises the sessions that are 
conducted one-on-one with the participant and with the aid of the 
caregiver when required. The training sessions are divided into four 
training sections; static balance, dynamic balance, functional practice, and 
progressive resistive exercise (detailed in Fig. 2). Balance tasks and func-
tional practice are performed prior to resistance exercise in order to 
avoid fatigue in the participant. The participant and caregiver are pro-
vided with a small snack following the sessions that contains approxi-
mately 13 g of protein and 1100 kj of energy. The study coordinator calls 
the caregiver weekly to monitor the status of the participant and 
response to exercise, as well as record any adverse events or changes in 
medications. Details of each intervention component are described 
below, and in Fig. 2. 
2.3.2.1. Static balance. Static balance is performed for a maximum of 
10 min of the total session duration inside a custom-built apparatus 
(Fig. 3). The participant stands in a position that challenges their 
postural stability, which is determined by choosing the most challenging 
balance position (e.g., narrow stance, tandem, etc.) that the participant 
had been able to hold for 15 s during the assessment before intervention. 
The participant interacts with the apparatus, a network of magnetic 
whiteboards positioned on a semi-immersive frame, by moving coloured 
button magnets in various tasks requiring manual dexterity, visuospatial 
and executive function, and reaching outside of the centre of gravity. 
The tasks progress with increasing cognitive and physical difficulty until 
performance plateaus, after which the stance position is progressed to a 
more unstable/difficult stance. The apparatus was purposely con-
structed to provide a safe area for the participant to stand with the 
assessor providing support if needed and direction from behind the 
participant. The dual-task activities are designed to promote natural, 
random movements outside of the centre of gravity and balance recov-
ery manoeuvres performed under challenging cognitive conditions, 
which have been shown to improve balance and reduce falls risk in older 
adults [28,29]. 
2.3.2.2. Dynamic balance. Dynamic balance is performed by instructing 
the participant to walk in tandem for 5 m along a red tape line. The 
participant walks in tandem along the length, around a cone and returns 
the length in tandem while performing a physical dual-task (plate 
holding), with the addition of a cognitive task as the difficulty pro-
gresses. The assessor closely follows the participant for safety, and 
provides performance prompts and imagery such as walking with ‘light 
feet on squeaky floorboards’ to encourage fast moving feet and smooth 
movements. Prompting the participant to concurrently walk in tandem 
as fast as possible with minimal errors, and simultaneously perform the 
cognitive task to their best ability creates the challenging conditions 
necessary to improve performance in complex daily conditions in PD 
cohorts [28,29]. 
2.3.2.3. Functional training. Specific functional deficits identified dur-
ing baseline assessment are practised during the session for a total of 
5 min. Safe technique for daily tasks such as chair stands or descents and 
walking are practised under the supervision of the EP. Specific items 
practiced include correctly shifting gravity forward to rise from a chair 
with minimal assistance, locating the armrest of the chair before 
descending, and practising smooth walking in a controlled environment 
with no walking aids, under contact guard. 
2.3.2.4. Progressive resistance exercise. The machine-based exercises 
(Fig. 2) are performed using K400 Keiser pneumatic machines (Keiser 
Sports Health Equipment, Ltd, Fresno, CA, USA) and are prescribed to 
participants to appropriately target muscle groups associated with 
maintaining independence, reducing falls risk, and aiding in posture in 
older adults [30,31]. The volume for each exercise consists of 2 sets of 6 
repetitions at the target load for the session, and is chosen to provide 
Fig. 1. Study design flow chart .  
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sufficient dose [32] in the limited, 40-min duration allocated to PRT. 
The initial intensity is set at 70% of the testing 1RM and progresses to 
80% 1RM by the 2nd week as previously described in PRT in older adults 
[33]. The intensity is progressed for a given exercise when the partici-
pant or assessor rating of perceived exertion (RPE) on the OMNI-Res 
scale [34] falls below 8/10, indicating that training adaptation has 
occurred for a given load. The concentric phase of each exercise is 
executed fast to target muscle power, with power training at higher 
loads appropriate for older adults and those with parkinsonism due to a 
greater contribution of load rather than speed to peak power [35,36]. 
The eccentric phase is executed slowly to enhance metabolic benefit and 
hypertrophy [24]. The target tempo is 1 s concentric, no pause, and 3 s 
eccentric (1-0-3). Auditory (lobby bell, verbal encouragement) and so-
matosensory (tapping target muscle) cueing are engaged to promote fast 
movement initiation and sustain high intensity [35,37]. 
Fig. 2. Exercise prescription - The four exercise components are combined sequentially in a 60-min session. The order of completion for each of the exercise 
components follows the order in the table, and is adjusted as tolerated by the participants. 
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2.3.3. Adverse events 
Monitoring of adverse events and all changes in health status and 
medical care/interventions is carried out via weekly telephone ques-
tionnaires with the caregiver and interview within sessions. Additional 
information is gathered from medical and nurse care teams if appro-
priate for participants residing within aged care facilities. Adverse 
events are defined a priori and include any exacerbation of underlying 
disease, or new onset musculoskeletal, cardiovascular or metabolic ab-
normalities. The study geriatrician and ethics committee evaluate all 
adverse events to ascertain if there is any relation to the study exercise or 
assessment protocols or need to change the study protocol. 
2.3.4. Following trial completion 
Following completion of the trial, participants are invited to 
continue exercising within the medically supervised clinic at no addi-
tional cost under the supervision of the clinic staff and students. There is 
no obligation to continue exercise beyond the study nor is there a limit 
on the total duration of participation beyond the trial. 
2.4. Measures 
The assessment battery (Table 1) was selected to evaluate the po-
tential contributions of a wide range of factors to functional indepen-
dence and quality of life in individuals with LBD. 
2.4.1. Primary outcomes 
2.4.1.1. Functional independence. Functional independence is measured 
via the total and sub-scores of the Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale (MDS-UPDRS) [38], which is an 
effective tool for evaluating disease severity, disability and indepen-
dence in Parkinsonian disorders including LBD [39]. The original and 
current version of scale has been used to track changes in disease status 
previously in PD cohorts after exercise interventions [40,41], and is 
correlated with quality of life and independence [42,43]. 
Fig. 3. Static balance dual-task apparatus - The custom-made apparatus, 
affectionately named ‘Humphre’ - consists of coloured button magnets, and 
magnetic whiteboards laterally, in front, and above the participant to allow 
completion of physical and cognitive dual-task. A grab bar in front of the 
participant provides additional support during the movement. 
Table 1 
Primary and secondary outcome measures.  
Domain Description 
Measure 
Primary outcome measures 
Functional independence 
Movement Disorder Society Unified 
Parkinson’s Disease Rating Scale 
(MDS-UPDRS) – sub scores and total 
score 
A clinical rating scale validated in 
Parkinsonian cohorts involving four 
parts: Non-motor experiences of daily 
living, motor experiences of daily living, 
motor examination, motor 
complications. Total score (/272) and 
sub-scores used to capture change in 
disease-related function and 
independence, with higher scores 
indicating greater disease related 
disability and symptom burden [38]. 
Secondary outcome measures 
Functional independence 
Bayer-instrumental Activities of Daily 
Living (B-ADL) 
The B-ADL is a 25-item informant or 
questionnaire sensitive to changes over 
time developed for pharmaceutical 
trials in dementia, and a valid indicator 
of functional impairments attributed to 
cognitive deficits. An averaged score 
between 1.00 and 10.00 is generated, 
whereby lower scores indicate less 
impairment in daily tasks [44]. 
Functional Independence Measure (FIM) A scale used to track changes in patient 
disability comprising of 18 items 
grouped into motor and cognition parts. 
Scale applied in outpatient setting using 
caregiver reports and objective testing 
to summate functional independence. 
Scored between 18 and 128 with a 
higher score indicating greater levels of 
independence [45]. 
Cognitive 
Mini-mental State Exam (MMSE) Well-validated, brief screening measure 
of cognitive function with sensitivity to 
changes over time. Scores range from 
0 to 30, with higher scores indicating 
better function. Scores <24 suggestive 
of moderate or greater cognitive 
impairment [46]. 
Parkinson’s Disease Cognitive Rating 
Scale (PD-CRS) 
A comprehensive 9-part cognitive 
assessment specific to deficits typically 
observed in Parkinsonian disorders 
(executive function, visuospatial 
dysfunction) and very sensitive and 
specific to LBD. A higher score indicates 
better cognitive function, up until a 
maximum score of 134 [47]. 
Trail-making (TMT) A & B Trials A & B evaluate speed of attention, 
sequencing, visual search and include a 
motor component. Trails B also assesses 
executive function [48]. This domain is 
known to be impaired in LBD [49]. 
Higher scores (time) taken to complete 
each tasks indicates greater impairment. 
Benton Visual Retention Test (BVRT) A visual memory and reconstruction test 
that evaluates visuospatial memory 
from simple designs and motor function. 
Sensitive to impairments specific to LBD 
[49]. Scored using an ‘all-or-nothing’ 
system whereby each of the 10 attempts 
are given ‘0’ for incorrect image or ‘1’ 
for correct image for a maximum of 10 
points, where Higher scores indicate 
better function [50]. 
Psychiatric 
Geriatric Depression Score – 15 item 
(GDS-15) 
A screening test used to assess level of 
depression in older adults with simple 
yes/no responses validated against 
structured clinical interview with good 
sensitivity and specificity. Designed to 
focus on non-somatic symptoms of 
(continued on next page) 
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Table 1 (continued ) 
Domain Description 
Measure 
depression to avoid overlap with 
physical illnesses in older adults. Higher 
scores indicate increasing depressive 
symptoms. A score of >5/15 is 
suggestive of depression, with higher 
scores indicating more depressive 
symptoms [51]. 
Neuropsychiatric Inventory (NPI) A comprehensive clinician-administered 
tool designed for proxy-reporting, 
involving 10 scored domains of 
behavioural disturbance occurring in 
dementia, and two additional domains 
involving sleep disturbances and eating 
behavior which do not form part of the 
final score. Presence of symptom, 
frequency, severity and caregiver 
distress rated for each relevant item. A 
symptom score (/12) and caregiver 
distress score (/5) is generated for each 
domain with higher scores indicating 
greater symptom impact and distress 
respectively [52]. 
Quality of life 
Dementia Quality of Life Scale & Proxy 
version (DEMQoL, DEMQoL - Proxy) 
DEMQoL is a 28-part questionnaire 
administered to person with dementia 
asking questions relating to quality of 
life items potentially affected by 
symptoms of dementia. DEMQoL- 
PROXY is a 31-items questionnaire 
administered to the caregiver of the 
person with dementia asking about the 
perceived quality of life of the care 
recipient. Higher scores for both 
measures indicate better quality of life 
for the participants, with a Likert scale 
from ‘1’ – all the time, to ‘4’ not at all, 
being used to rate the frequency of each 
concern [53]. 
Satisfaction with Life Scale (SWLS) A global 5-item scale rating overall life 
satisfaction. Rated on a 7-point scale 
from strongly disagree to strongly agree. 
Scored between 5 and 35, with higher 
scores indicating greater relative 
satisfaction with life, and 20/35 
considered a neutral point between 
dissatisfaction and satisfaction with life 
[54]. 
University of Alabama Study of Ageing – 
Life Space Assessment (LSA) 
The LSA provides insight into the 
mobility and travel patterns of the 
person within home and community 
ranging from in bedroom to unrestricted 
travel zones outside of community. The 
LSA is associated with quality of life and 
disability. Scored from 0 to 120 with a 
higher score indicating a greater life- 
space [55]. 
Physiological capacity 
Muscle strength Maximal dynamic lower and upper 
extremity strength obtained using the 
digital K400 Keiser pneumatic machines 
(Keiser Corp, Fresno, CA, USA). 
Isometric strength assessed using the 
Chatillon CSD200 force dynamometer 
(Ametek Inc., Largo, FL USA) at all 
timepoints. Muscle groups assessed 
included hip and knee extensors, hop 
abductors, and triceps extension. 
Isometric handgrip strength Isometric strength of dominant and non- 
dominant hand assessed using JAMAR 
handgrip dynamometer (Sammons 
Preston, Bolingbrook, IL). Highest result 
of 3 trials in each hand used for analysis. 
A grip strength of <27 kg is a cut off 
point for sarcopenia [56].  
Table 1 (continued ) 
Domain Description 
Measure 
6-min walk distance (6MWD) Widely used test of walking endurance, 
which is a proxy for overall 
cardiovascular endurance in elderly 
adults with comprehensive normative 
data [57]. Total distance walked within 
6 min recorded along with stoppages 
Static balance Assessed for 15 s in six different 
conditions (wide, narrow, semi-tandem 
and tandem stance, and on one leg 
without and with eyes closed). 2nd, 3rd 
and 4th position used in SPPB score 
calculation with 10s cut off. 
Tandem walk A heel-to-toe walk over 3 m performed 
at maximal pace with as minimal errors 
as possible. Two trials performed and 
fastest time used for analysis. 
Physical performance 
Gait speed – Habitual and maximal Habitual measured over a 3-m course 
with a stopwatch as specified in SPPB 
protocol [58], then measured along with 
maximal gait speed over 2-m distance 
from a dynamic start with an Ultra-timer 
(Raymar, Oxfordshire, UK). Average of 
times ultra-timer times used for 
analysis. A habitual walking speed of 
0.8 m/s or less is a cut off for sarcopenia 
[56]. 
Chair stand A proxy for lower extremity power, or 
the ability to generate high forces 
rapidly. Primarily, participants used hip 
and knee extensors muscles. Time taken 
to complete 5 stands recorded and used 
in the SPPB score calculation. A time of 
more than 15 s for the 5 stands is a cut 
off for sarcopenia [56]. 
Short Physical Performance Battery 
(SPPB) 
Performance-based testing of functional 
mobility generating a score up to 4 
points for three domains (gait speed, 
static balance, chair stand) for a total of 
12 points. Higher score is indicative of 
better function and strongly predictive 
of mortality and nursing home 
placement [58]. A score of 8 or less is a 
cut-off for sarcopenia [56]. 
Cardiovascular 
Orthostatic blood pressure (BP) and heart 
rate (HR) 
Measurement of orthostatic hypotension 
and HR in fasting state with rest 
(>5 min) in supine position, and then in 
standing position at 1 and 3 min. A drop 
in systolic of 20 mmHg and/or diastolic 
of 10 mmHg is indicative or orthostatic 
hypotension. HR response can also be 
suggestive of cause [59]. 
Body composition 
Anthropometry Stretch stature height (BL only), weight 
(kg), and waist circumference (cm) are 
obtained in triplicate after overnight 
fast. BMI calculated (weight kg/height 
m2). 
Bioelectrical Impendence Analysis (BIA) Whole body skeletal muscle mass (kg), 
fat free mass (kg) and skeletal muscle 
index calculated** using average 
resistance and reactance values 
measured in supine, fasted state with 
BIA analyser (RLJ Prizum, S/N 
B10875E, Mode BIA-101s) 
Mini Nutritional Assessment –Short Form 
(MNA-SF) 
A short clinician rated form to assess risk 
of malnutrition in elderly patients based 
on risk factors for reduced dietary 
intake. Score out of 14, with a score less 
than 8 considered malnourished [60]. 
Health status 
Medical history Comprehensive physician screen 
performed by study Geriatrician 
(continued on next page) 
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2.4.2. Secondary outcomes 
A range of secondary outcomes including cognition, psychosocial, 
quality of life, cardiovascular, body composition, health status, physical 
performance, exercise capacity and additional function independence mea-
sures are assessed. Additionally, caregiver burden and psychosocial out-
comes are assessed. Table 1 details the total list of assessments 
performed. 
2.5. Statistical analysis 
All data will be evaluated visually and statistically for normality of 
distribution, and transformed prior to use in parametric statistics as 
required. Descriptive measures will be generated from the baseline 
cross-sectional data, including means (standard deviations), medians 
(ranges) or frequencies, as appropriate. Associations between variables 
of interest will be evaluated through simple linear regression for nor-
mally distributed data; otherwise Spearman’s correlation will be used. 
Primary intention-to-treat (ITT) analysis for all primary and secondary 
outcomes will be conducted using repeated-measures mixed models 
across all three time points: Baseline (T1), prior to exercise (T2), and 
after exercise (T3). A secondary all-available data (AAD) analysis will be 
conducted using repeated measures analysis of variance (ANOVA). 
Statistical significance will be defined as α < 0.05. When the main effect 
of TIME is significant in mixed models or ANOVAs, all pairwise com-
parisons will be analysed via post-hoc Bonferroni post-hoc t tests to 
investigate differences across the wait-list, intervention, and total trial 
periods. Additionally, Cohen’s d effect sizes (ESs) will be calculated for 
primary and secondary outcomes during the exercise intervention 
period using the formula:  
T3 – T2 / SDT2.                                                                                      
Interpretation of these ESs will conform to standard definitions of 
small (0.2-<0.5), medium (0.5–0.8), and large (>0.8). Feasibility will be 
assessed via adoption & adherence rates; reported as percentage 
completion and compared with reported adherence from similar co-
horts. Safety will be monitored via tabulation of adverse events ascer-
tained from a variety of sources as described in Section 2.3.3. Statistical 
analysis will be performed using SPSS software (Version 26, SPSS, Inc, 
Chicago). 
3. Discussion 
The primary aim of this study is to evaluate the determinants of 
functional independence in LBD and the effect of a targeted exercise 
intervention. LBD is a disease with complex, rapid progressing and 
fluctuating symptoms, which warrants the assessment of a comprehen-
sive range of clinically meaningful outcomes including physical func-
tion, strength, cognition, quality of life, psychiatric, and nutritional 
outcomes. Unfortunately, individuals with LBD are often excluded from 
trials of exercise in PD and other dementias due to this complex com-
bination of motor and cognitive symptoms, which are perceived as 
potentially compromising to the homogeneity of cohort characteristics 
and adaptations(14). Additionally, the fluctuating nature of the disease 
course and difficulty with recruitment is a major barrier to conducting 
exercise research in this cohort, just as it is for the conduct of pharma-
ceutical trials in LBD(2). As a result, the literature pertaining to exercise 
and LBD is scarce, and consists of only a few case reports and fragments 
of trial data evaluating non-anabolic, motor interventions such as low 
intensity recumbent cycling, skill, and gait training. 
The PRIDE study is the first empirical trial evaluating the feasibility 
of an exercise intervention in LBD, and will provide much needed data to 
contribute to the under-researched field of non-pharmacological thera-
pies in LBD. As such, the trial responds to recommendations from the 
international Forth Consensus Report of the DLB Consortium to develop 
and evaluate non-pharmacological therapies in this disease [67]. The 
data collected from this pilot study will provide valuable information on 
ESs for the major outcomes, and thus refine estimates of samples sizes 
requirements for adequately powered future trials. In addition, the 
feasibility of assessment tools and training techniques in this population 
will be evaluated. Importantly, the PRIDE Study will provide an op-
portunity for those individuals typically excluded from clinical trials to 
participate in an intervention specifically designed for their needs while 
advancing knowledge in this field. 
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Table 1 (continued ) 
Domain Description 
Measure 
involving past medical history, review 
of systems examination 
Habitual physical activity Habitual physical activity, sedentary 
time and sleep patterns will be recorded 
using activity monitors (AX3, Axivity, 
Newcastle upon Tyne, UK) worn on 
lumbar spine. 
Clinical Dementia Rating (CDR) Commonly used dementia assessment 
tool for the assessment of dementia 
severity. Completed by clinician in 
conjunction with cognitive testing, and 
informant reports. Domain ratings range 
from 0 (no impairment) to 3 (sever 
impairment) and an algorithm using the 
total sum of domain scores (/18) is used 
to produce a summary score from 0 to 3 
[61]. 
Adverse events Any adverse events that occur during 
the study period will be detailed and 
adjudication from study geriatrician and 
ethics committee will inform whether 
related or unrelated to intervention. 
Caregiver psychiatric and quality of life 
Geriatric Depression Scale (GDS-15) 
Satisfaction With Life Scale (SWLS) 
See secondary outcomes – psychiatric 
section in table for description. 
See secondary outcomes – quality of life 
section in table for description. 
Positive and Negative Affect Scale 
(PANAS) 
A scale consisting of 10 positive items 
and 10 negative items to measure affect. 
Rated from not feeling a particular 
emotion [1] to feeling the emotion 
extremely [5] over a period of a few 
hours. A score range between 10 and 50 
is generated separately for both positive 
affect items and negative affect items. In 
the positive items a higher score 
indicates more positive affect, and lower 
scores on the negative items indicate 
less negative affect [62]. 
Quality of Life Scale (QOLS) A 5-domain scale consisting of 16 items 
evaluating quality of life in the 
caregiver. Total score summated. Scored 
between 16 and 112 with a higher score 
indicating greater overall quality of life 
[63]. 
Zarit Burden interview-22 item A 22-item scale measuring levels of 
caregiver burden relating to the care of a 
person with dementia and correlated 
with behavioural problems in care 
recipient and depression in caregiver. 
Rated from 0 to 88, a higher score 
indicates increased caregiver burden 
[64]. 
** *Skeletal muscle mass (SMM)  0.401(height in cm2/resistance in ohms)
3.825 (sex: male  1; female  0)age in years(-0.071)  5.102 [65]. Fat-free 
mass (FFM)    4.03  0.734 (height in cm2/resistance in ohms) 0.116 
(body weight in kg)  0.096 (reactance in ohms) 0.984 (sex: male  1; female 
 0) [66]. 
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